Recently published multisociety guidelines for the management of dyslipidemia emphasize early identification and treatment of dyslipidemia to reduce the lifetime risk of atherosclerotic cardiovascular disease (ASCVD) and death.1
LIPOPROTEIN GOALS — The updated guideline now recommends specific lipoprotein goals to guide treatment and reduce ASCVD risk (see Table 1). For primary prevention, the recommended low-density lipoprotein cholesterol (LDL-C) goal is 40 mg/day of pravastatin may increase the risk of myopathy...
ISSUE
The FDA has approved orforglipron (Foundayo – Lilly), an oral small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and at least one weight-related comorbidity. Orforglipron is the second oral GLP-1 receptor agonist to be approved in the US for this indication; an oral formulation of the peptide semaglutide (Wegovy) was approved in 2025.1
MECHANISM OF ACTION ― Activation of GLP-1 receptors in the brain reduces appetite and cravings and promotes satiety. Activation of these receptors in the GI system potentiates glucose-dependent secretion of insulin, suppresses glucagon secretion, and slows gastric emptying.2
CLINICAL STUDIES ― FDA approval of orforglipron was based on the results of two double-blind trials (ATTAIN-1 …